6-K

QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

May 6, 2003

Commission File Number 001-11145

BIOVAIL CORPORATION
(Translation of Registrant's name into English)

7150 Mississauga Road, Mississauga, Ontario, CANADA, L5N 8M5
(Address of principal executive office and zip code)

Registrant's telephone number, including area code: (905) 286-3000

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ý                        Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

Yes o                        No ý

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

Yes o                        No ý

Indicate by check mark whether by furnishing the information contained in this form the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g 3-2(b) under the Securities Exchange Act of 1934.

Yes o                        No ý

BIOVAIL CORPORATION

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form S-8 (Registration No. 333-92229) and on Form F-10 (Registration No. 333-14048) of Biovail Corporation.

INDEX

        Exhibit 99.1 — Material Change Report Dated May 5, 2003

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Biovail Corporation
Date: May 6, 2003	By:	/s/  JOHN R. MISZUK John R. Miszuk Vice President, Controller and Assistant Secretary

1

QuickLinks

BIOVAIL CORPORATION
INDEX
SIGNATURES

EX-99.1

QuickLinks -- Click here to rapidly navigate through this document

MATERIAL CHANGE REPORT

PURSUANT TO

SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)
SECTION 146(2) OF THE SECURITIES ACT (ALBERTA)
SECTION 84(1) OF THE SECURITIES ACT (SASKATCHEWAN)
SECTION 75(2) OF THE SECURITIES ACT (ONTARIO)
SECTION 73 OF THE SECURITIES ACT (QUEBEC)
SECTION 81(2) OF THE SECURITIES ACT (NOVA SCOTIA)
SECTION 76(2) OF THE SECURITIES ACT (NEWFOUNDLAND)

ITEM 1:	REPORTING ISSUER
	Biovail Corporation 7150 Mississauga Road Mississauga Ontario L5N 8M5
ITEM 2:	DATE OF MATERIAL CHANGE
	April 25, 2003
ITEM 3:	PRESS RELEASE
	The attached press release was issued by Biovail Corporation on April 25, 2003 and filed on SEDAR on May 2, 2003.
ITEM 4:	SUMMARY OF MATERIAL CHANGE
	Appointment of Gregory Szpunar as Senior Vice President, Research & Development and Chief Scientific Officer
ITEM 5:	FULL DESCRIPTION OF MATERIAL CHANGE
	See press release attached as Schedule A.
ITEM 6:	RELIANCE ON CONFIDENTIALITY SECTION OF THE ACT
	Not applicable.
ITEM 7:	OMITTED INFORMATION
	Not applicable.
ITEM 8:	SENIOR OFFICER — FOR FURTHER INFORMATION CONTACT:
	For further information, contact Ken Howling at 905-286-3000.

ITEM 9:	STATEMENT OF SENIOR OFFICER
	The foregoing accurately discloses the material change referred to herein.
	DATED May 5, 2003.

BIOVAIL CORPORATION
By:	Name: Kenneth C. Cancellara, Q.C. Title: Senior Vice President, Chief Legal Officer & Corporate Secretary

        IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.

	CONTACT:	Kenneth G. Howling Vice President, Finance (905) 286-3000
FOR IMMEDIATE RELEASE:

BIOVAIL APPOINTS GREGORY SZPUNAR
SENIOR VICE PRESIDENT, RESEARCH & DEVELOPMENT
AND CHIEF SCIENTIFIC OFFICER

        TORONTO, Canada, April 25, 2003 — Biovail Corporation (NYSE, TSX: BVF) announced today that Gregory J. Szpunar, Ph.D., has been appointed Senior Vice President, Research and Development, and Chief Scientific Officer, effective April 21, 2003. Dr. Szpunar will be responsible for directing Biovail's research and development activities as well as the company's manufacturing operations. Dr. Szpunar will report to Eugene Melnyk, Chairman and Chief Executive Officer, Biovail Corporation.

        Dr. Szpunar served as Senior Vice President, Product Development at Pharmacia Corporation until its acquisition by Pfizer, which was completed on April 15, 2003. Dr. Szpunar's 19-year tenure in the industry includes participation in and responsibility for directing global R&D operations ranging from early pre-clinical development through Phase IV product support. He has served in direct leadership positions in clinical and pre-clinical pharmacokinetics and drug metabolism, biopharmaceutics research, project management, portfolio analysis, and quality assurance. In addition, Dr. Szpunar has participated in the strategic governance of R&D ranging from early discovery research through product life cycle management.

        Dr. Szpunar played a pivotal role in the design and implementation of Pharmacia's Customer Focused Product Flow process, which emphasized seamless collaboration between research & development, marketing and sales, manufacturing, and business development resulting in highly coordinated discovery, development, and commercial activities that optimized the commercial and technical potential of each product.

        Dr. Szpunar holds a Ph.D. in Pharmaceutics from the University of Michigan, and a B.S. in Pharmacy from Wayne State University.

        "Biovail research and development activities are expanding at an unprecedented rate", commented Eugene Melnyk. "We have over 30 disclosed and undisclosed active development programs including numerous ongoing Phase III and Phase IV clinical programs. As well, we are actively exploring many new product development and venture opportunities, all of which require technical and manufacturing assessments. The addition of Dr. Szpunar to Biovail's senior executive team will strengthen its capabilities in this area and will streamline the necessary transition from formulation to full-scale commercial manufacturing."

        Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies.

        For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.

QuickLinks

MATERIAL CHANGE REPORT
BIOVAIL APPOINTS GREGORY SZPUNAR SENIOR VICE PRESIDENT, RESEARCH & DEVELOPMENT AND CHIEF SCIENTIFIC OFFICER